Brown, S.R.; Vomhof-DeKrey, E.E.; Al-Marsoummi, S.; Beyer, T.; Lauckner, B.; Samson, M.; Sattar, S.; Brown, N.D.; Basson, M.D.
SLFN12 Expression Significantly Effects the Response to Chemotherapy Drugs in Triple-Negative Breast Cancer. Cancers 2024, 16, 3848.
https://doi.org/10.3390/cancers16223848
AMA Style
Brown SR, Vomhof-DeKrey EE, Al-Marsoummi S, Beyer T, Lauckner B, Samson M, Sattar S, Brown ND, Basson MD.
SLFN12 Expression Significantly Effects the Response to Chemotherapy Drugs in Triple-Negative Breast Cancer. Cancers. 2024; 16(22):3848.
https://doi.org/10.3390/cancers16223848
Chicago/Turabian Style
Brown, Savannah R., Emilie Erin Vomhof-DeKrey, Sarmad Al-Marsoummi, Trysten Beyer, Bo Lauckner, Mckenzie Samson, Sarah Sattar, Nicholas D. Brown, and Marc D. Basson.
2024. "SLFN12 Expression Significantly Effects the Response to Chemotherapy Drugs in Triple-Negative Breast Cancer" Cancers 16, no. 22: 3848.
https://doi.org/10.3390/cancers16223848
APA Style
Brown, S. R., Vomhof-DeKrey, E. E., Al-Marsoummi, S., Beyer, T., Lauckner, B., Samson, M., Sattar, S., Brown, N. D., & Basson, M. D.
(2024). SLFN12 Expression Significantly Effects the Response to Chemotherapy Drugs in Triple-Negative Breast Cancer. Cancers, 16(22), 3848.
https://doi.org/10.3390/cancers16223848